Corcept Therapeutics AI Stock Analysis
Want to see CORT full AI Analyst Report?
Corcept Therapeutics (CORT) AI Stock Analysis
Corcept Therapeutics
(NASDAQ:CORT)
CORT scores well on financial quality (strong cash generation and a very low-debt balance sheet) and is supported by a highly constructive earnings update with reiterated guidance and meaningful pipeline/commercial momentum. The score is held back by weak technicals (bearish trend despite oversold readings) and a rich valuation (high P/E with no dividend yield provided).
Corcept Therapeutics Key Performance Indicators (KPIs)
Research & Development Expense BreakdownAllocation of R&D spending across programs and trial stages reveals how Corcept is prioritizing its pipeline—whether cash is focused on late‑stage clinical trials that could produce near‑term approvals and revenue, or on early discovery that points to longer‑term growth. Changes in the mix and absolute R&D spend also signal the company’s cash burn and financing needs, the surface area for regulatory and clinical risk, and how management balances short‑term commercial support with long‑term drug development.
R&D spending is clearly being reallocated: after a multi‑quarter surge in hypercortisolism investment (driving Cushing’s/relacorilant activity), a sharp Q2‑2026 drop points to a transition from late‑stage development to regulatory/commercial execution—consistent with Lifyorli’s approval and management’s commercial focus—while oncology and pre‑clinical/ALS budgets are ramping, and unallocated/stock‑comp costs are rising as the company scales. That shift supports the raised 2026 guidance but raises execution risk if reduced metabolic R&D limits future indication expansion.
Corcept Therapeutics (CORT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $7.67B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.25M
- Price to Earnings (P/E)
- 46.5
- Beta (1Y)
- 0.35
- Revenue Growth
- 30.02%
- EPS Growth
- 48.80%
- Country
- US
- Employees
- 730
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Corcept Therapeutics Business Overview & Revenue Model
Company Description
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychia...
How the Company Makes Money
Corcept primarily makes money from net product revenue generated by sales of its marketed drug, Korlym (mifepristone), in the United States. Revenue is recognized from product shipments/sales to customers, net of estimated allowances such as product...
Corcept Therapeutics Earnings Call Summary
The call was strongly positive, with substantial revenue and net-income growth, record endocrinology performance, rapid Lifyorli adoption, positive clinical results and multiple advancing pipeline programs. The company also reiterated its 2026 revenue guidance and highlighted significant future opportunities in Cushing's syndrome, oncology, MASH and ALS. The main negatives were the prior complete response letter for relacorilant, the continuing underdiagnosis of hypercortisolism, the unmet need in platinum-resistant ovarian cancer and limited available information on a potential competing therapy.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Corcept reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion, with the midpoint of the range as its best thinking, and said it expects growth to continue; it expects its current Cushing's syndrome business to generate at least $2 billion in annual revenue by the end of this decade, with the availability of relacorilant driving faster growth to between $3 billion and $5 billion in 2030, while Lifyorli is expected to generate more than $1 billion. The company expects results from its BELLA, TRIDENT and SYNERGY studies by the end of next year, plans to begin a Phase III study in ALS next year, and will soon start a Phase II MASH trial evaluating 100 milligrams of miricorilant daily.
Corcept Therapeutics Financial Statement Overview
Summary
High-quality fundamentals: strong TTM revenue growth (~16%) with attractive net margin (~16.6%), very conservative leverage (debt-to-equity ~0.01), and robust/free-cash-flow strength (TTM FCF ~$195M; ~82% growth) with solid cash conversion (~0.98 FCF/NI). The main constraint is the recent step-down in operating margin and moderated return efficiency versus prior years.
Income Statement
78PositiveBalance Sheet
92Very PositiveCash Flow
88Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 963.65M | 761.41M | 675.04M | 482.38M | 401.86M | 365.98M |
| Gross Profit | 949.55M | 748.43M | 664.16M | 475.89M | 396.47M | 360.70M |
| EBITDA | 134.40M | 68.35M | 162.83M | 126.92M | 119.64M | 127.95M |
| Net Income | 162.00M | 99.65M | 139.73M | 106.14M | 101.42M | 112.51M |
Balance Sheet | ||||||
| Total Assets | 1.03B | 836.65M | 840.55M | 621.52M | 583.43M | 423.76M |
| Cash, Cash Equivalents and Short-Term Investments | 370.70M | 372.15M | 383.33M | 368.22M | 431.67M | 223.53M |
| Total Debt | 8.99M | 6.11M | 6.94M | 151.00K | 1.14M | 526.00K |
| Total Liabilities | 200.29M | 188.85M | 160.96M | 114.81M | 81.59M | 47.95M |
| Stockholders Equity | 833.74M | 647.80M | 679.59M | 506.70M | 501.84M | 375.81M |
Cash Flow | ||||||
| Free Cash Flow | 194.62M | 141.78M | 195.90M | 126.90M | 119.91M | 167.42M |
| Operating Cash Flow | 198.11M | 142.00M | 198.07M | 127.04M | 120.32M | 167.89M |
| Investing Cash Flow | -168.53M | 69.76M | -177.60M | 90.91M | -114.33M | 136.13M |
| Financing Cash Flow | -56.38M | -220.37M | -28.35M | -148.72M | -17.28M | -302.59M |
Corcept Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CORT, the sentiment is Negative. The current price of 70.07 is below the 20-day moving average (MA) of 81.63, below the 50-day MA of 101.97, and below the 200-day MA of 76.79, indicating a bearish trend. The MACD of -9.76 indicates Positive momentum. The RSI at 25.30 is Positive, neither overbought nor oversold. The STOCH value of 13.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CORT.
Corcept Therapeutics Risk Analysis
Corcept Therapeutics disclosed 29 risk factors in its most recent earnings report. Corcept Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksCorcept Therapeutics Peers Comparison
Overall Rating
KNSA80Outperform
CORT71Outperform
LQDA60Neutral
SCYX53Neutral
CTOR44Neutral
NSRX28Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | $7.47B | 66.08 | 17.27% | ― | 58.19% | 192.34% | |
| 71Outperform | $7.67B | 46.55 | 22.94% | ― | 30.02% | 48.80% | |
| 60Neutral | $5.11B | -54.32 | -116.64% | ― | 798.44% | 27.88% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 53Neutral | $28.37M | -2.44 | -18.65% | ― | 543.96% | 72.49% | |
| 44Neutral | $50.92M | -1.20 | -102.97% | ― | ― | ― | |
| 28Underperform | $30.57M | -2.54 | -158.83% | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CORT | Corcept Therapeutics | 70.07 | -4.98 | -6.64% | |
| SCYX | SCYNEXIS Inc | 2.85 | -2.67 | -48.37% | |
| KNSA | Kiniksa Pharmaceuticals Ltd. Class A | 95.11 | 53.62 | 129.24% | |
| LQDA | Liquidia Technologies | 56.73 | 28.17 | 98.63% | |
| CTOR | Citius Oncology, Inc. | 0.55 | -0.58 | -51.59% | |
| NSRX | Nasus Pharma Ltd. | 2.61 | -4.39 | -62.71% |
Corcept Therapeutics Corporate Events
Corcept Therapeutics Reports Strong Third-Quarter Revenue and Earnings Growth
PositiveOn November 3, 2026, Corcept reported third-quarter revenue of $340.5 million, up 64% from the same period in 2025. Net income rose to $126.8 million from $19.7 million, while diluted earnings per share increased to $1.01 from $0.16 and cash and inve...
Corcept Therapeutics Announces New Endocrinology Division President
PositiveOn September 22, 2026, Corcept Therapeutics said Sean Maduck, president of its Endocrinology division, notified the board he would resign effective October 1, 2026, after a 14-year tenure in which he helped expand treatment for patients with Cushing’...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
